### INTERNATIONAL SEARCH REPORT

International application No. PCT/JP2005/002913

A.	CLASSIFICATION OF SUBJECT MA- Int.Cl <sup>7</sup> C07D209/08, A6		MATTER A61K31/4045,	A61P9/00,	13/10,	19/00,	25/02,	25/3	16,	
		25/28,	43/0	0						

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.C1<sup>7</sup> C07D209/08, A61K31/4045, A61F9/00, 13/10, 19/00, 25/02, 25/16, 25/28, 43/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAPLUS (STN), CAOLD (STN), REGISTRY (STN), MEDLINE (STN)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
Х	JP 2001-208115 A (Yamanouchi Pharmaceutical Co., Ltd.), 16 October, 2001 (16.10.01),		
	& CA 2435989 A & WO 2002/062390 A1 & EP 1358889 A1 & US 2004/072851 A1		
Y	JP 2000-247998 A (Kissei Pharmaceutical Co., Ltd.), 12 September, 2000 (12.09.00), (Family: none)	1-5	
¥	WO 99/15202 A1 (Kissei Pharmaceutical Co., Ltd.), 01 April, 1999 (01.04.99), 4 AU 9890959 A1	1-5	

101,7 01 April, 1999 (01.04.99), 4 AU 9890959 Al	
X Further documents are listed in the continuation of Box C.	See patent family annex.
Special categories of clast documents. Yet document disting the general state of the art which is not consistend to be of particular reference to the particular reference categories. The particular reference categories are particular reference categories. The particular reference categories ca	"I bet focuseet published after the international filting date or priority date and not in conflict with the application but cited to understand.  "X document of president eventures the chair and invention cannot be started in the conflict of the application of the cited to invention cannot be started by the conflict of the conflict
Date of the actual completion of the international search 31 March, 2005 (31.03.05)	Date of mailing of the international search report 19 April, 2005 (19.04.05)
Name and mailing address of the ISA/ Japanese Patent Office	Authorized officer
Facsimile No. Patent provided by Sughrue Mion.	(Indophyna Way sughrus.com

Facsimile No. Patent pro Form PCT/ISA/210 (second sheet) (January 2004)

## INTERNATIONAL SEARCH REPORT

International application No. PCT/JP2005/002913

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 99/48530 A1 (MERCK & CO., INC.), 30 September, 1999 (30.09.99), & AU 9930112 A1 & US 6410554 B1	1-5
Y	US 2002/143007 A1 (GARVEY, D.S.), 03 October, 2002 (03.10.02), & US 5932538 A & US 5994294 A & US 6294517 B1	1-5
Y	YAMADA, S., "In vivo receptor binding of novel KSYM971-adrenoceptor antagonists for treatment of benign prostatic hyperplasia, Life Sciences, 1938 Nen, Vol.62, No.17/18, pages 1935 to 1889	1-5
Y	CKURA, T., "Selective and sustained occupancy of prostatic <5WM9701-adrenoceptors by oral administration of KM070213 and its plasma concentration in rats", Journal of Pharmacy and Pharmacology, 2002 Nen, Vol.54, No.7, pp. 975-98	1-5
У	AKIYAMA, K., "Effects of KMD-3213, a uroselective <\$TMM97-1R-adrenoceptor antagonist on the tilt-induced blood pressure respose in normotensive rats", Japanese Journal of Pharmacology, 2002 Nen, Vol.90, No.2, pages 131 to 137	1-5
Y	Teruhisa OHASHI, Shinryo Kenkyu, "Hainyo Shogai to Nyo Shikkin (Ge)", Gekkan Hodanren, 1998 Nen, No.591, pages 57 to 60	1-5
Ā	Masataka YOSHIDA, "Kabu Nyoro Kino Kenkyu no Saikin no Shinpo: Kiso Kenkyu o kinaho Oyo ni Tsugu 3 Kabu Nyoro Heikatsukin Kino ni Kakawaru Shinkei Dentatsu Busshitsu no Yokurigakureki Bunseki", Folla Pharmacologica Japonica, 2003 Nen, Vol.121, No.5, pages 307 to 316	1-5
Y	Osamu ISHIDUKA, "Koreisha no Zenritsusen Shikkan Zenritsusen Shikkan to Kakatsudo Boko", Geriatr Med, 2003 Nen, Vol.41, No.8, pages 1149 to 1153	1-5
Y	ISHIZUKA O., Micturition in conscious rats with and without bladder outlet obstruction: role of spinal ol-adrenoceptors., Br.J.Pharmacol., 1996 Nen, Vol.117, No.5, pages 962 to 966	1-5
P,X	WO 2004/054574 A1 (Kissei Pharmaceutical Co., Ltd.), 01 July, 2004 (01.07.04),	1-5
	Patent provided by Sughrus Mion, PLLC - http://www.sughrus.com	

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2005/002913 C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT Relevant to claim No. Citation of document, with indication, where appropriate, of the relevant passages Category\* 1-5 WO 2004/022538 Al (Kissei Pharmaceutical Co., P,X Ltd.), 18 March, 2004 (18.03.04),

Patent provided by Sughrue Mion, PLLC - http://www.sughrue.com

#### (19) 世界知的所有棒機關 国際事務局



# 

#### (43) 国際公開日 2005年9月15日 (15.09,2005)

#### (10) 国際公開番号 PCT WO 2005/085195 A1

(51)	國際特許分類7:	C07D 209/08, A61K 31/4045, A61P		
	9/00, 13/10, 19/00	25/02, 25/16, 25/28, 43/00		

(21) 国際出頭番号: PCT/JP2005/002913

(22) 国際出麗日: 2005年2月23日(23.02.2005)

(25) 国際出頭の言語: 日本語 日本語

(26) 国際公開の言語: (30) 優先権データ: 特爾2004-061476 2004年3月5日(05.03.2004)

(71) 出願人 (米国を除く全ての措定国について): キッ セイ薬品工業株式会社 (KISSEI PHARMACEUTI-CAL CO., LTD.) [JP/JP]; 〒3998710 長野県松本市芳 野19番48号 Nagano (JP).

穂高町大字柏原4365-1キッセイ薬品工業株式 会計中央研究所内 Nagano (JP)。

(81) 指定国(表示のない限り、全ての程類の国内保護が 可能): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT. LU. LV. MA. MD. MG. MK, MN, MW. MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW,

(84) 指定国 (表示のない限り、全ての種類の広域保護 が可能): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), ユーラシア (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), ■ - □ ッパ (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE. IS. IT. LT. LU. MC. NL. PL, PT, RO, SE, SI, SK, TR), OAPI (BE BJ. CF. CG. CI. CM. GA. GN. GQ. GW. MI., MR. NR. SN. TD. TG).


(72) 発明者; および (75) 発明者/出願人 (米国についてのみ): 山崎 芳伸 (YA-

MAZAKI, Yoshinobu) [JP/JP]; 〒3998304 長野県南安 曼邦穂高町大学柏原4365-1 キッセイ薬品工業 株式会社中央研究所内 Nagano (JP). 今村卓広 (IMA-MURA, Takahiro) [JP/JP]: 〒3998304 長野県南安曇郡 添付公開書類: 国際調査報告書

2 文字コード及び他の略語については、定期発行される 各PCTガゼットの巻頭に掲載されている「コードと略語 のガイダンスノート」を参照。

(54) Title: MEDICINAL COMPOSITION FOR PREVENTION OR TREATMENT OF OVERACTIVE BLADDER ACCOMPA-NYING NERVOUS DISORDER

## (54) 発明の名称: 神経障害に伴う過活動膀胱の予防または治療用医薬組成物



(57) Abstract: A medicinal composition for the prevention or treatment of overactive bladder accompanying nervous disorders. The medicinal composition contains as an active n ingredient an indoline derivative represented by the following general formula (I) or a pharmacologically acceptable salt thereof. The medicinal composition is useful in the prevention or treatment of overactive bladder accompanying nervous disorders such as

cerebrovascular disorder, Parkinson's disease, and myclopathia. In the formula, R represents optionally substituted aliphatic acyl, optionally substituted lower alkyl, optionally substituted aromatic acyl, etc.; R1 represents cyano or carbamoyl; and R2 represents optionally substituted lower alkyl.

 (57) 薬物: 神経障害に伴う通活動膀胱を予防又は治療するための医薬組成物を提供する。 下記一般式 (I) で 表されるインドリン族導体またはその薬理学的に許容される塩を有効成分として含有する医薬組成物。 該医薬組成 物は、脳血管障害、パーキンソン病、脊髄障害等の神経障害に伴う過活動膀胱の予防又は治療に有用である。式中 のRは置換可脂肪族アシル基、置換可低級アルキル基、置換可芳香族アシル基等、R<sup>1</sup>はシアノ基又はカルパモイ ▲ ル基、R<sup>2</sup>は世換可低級アルキル基を表す。